WO2000006576A1 - Composes - Google Patents

Composes Download PDF

Info

Publication number
WO2000006576A1
WO2000006576A1 PCT/SE1999/001318 SE9901318W WO0006576A1 WO 2000006576 A1 WO2000006576 A1 WO 2000006576A1 SE 9901318 W SE9901318 W SE 9901318W WO 0006576 A1 WO0006576 A1 WO 0006576A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
pharmaceutically acceptable
tautomer
enantiomer
Prior art date
Application number
PCT/SE1999/001318
Other languages
English (en)
Inventor
Peter Hamley
Alan Tinker
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to AU56613/99A priority Critical patent/AU5661399A/en
Publication of WO2000006576A1 publication Critical patent/WO2000006576A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems

Definitions

  • the present invention relates to novel compounds which are aminospiropiperidine quinazoline derivatives.
  • the invention also concerns related aspects including processes for the preparation of the compounds, compositions containing them and their use as pharmaceuticals. There are also provided chemical intermediates useful for the production of the compounds.
  • Nitric oxide is produced in mammalian cells from L-arginine by the action of specific nitric oxide synthases (NOSs). These enzymes fall into two distinct classes - constitutive NOS (cNOS) and inducible NOS (iNOS). At the present time, two constitutive NOSs and one inducible NOS have been identified. Of the constitutive NOSs, an endothelial enzyme (ecNOS) is involved with smooth muscle relaxation and the regulation of blood pressure and blood flow, whereas the neuronal enzyme (ncNOS) serves as a neurotransmitter and appears to be involved in the regulation of various biological functions such as cerebral ischaemia. Inducible NOS has been particularly implicated in the pathogenesis of inflammatory diseases. Regulation of these enzymes should therefore offer considerable potential in the treatment of a wide variety of disease states (J. E. Macdonald, Ann. Rep. Med. Chem., 1996, 31, 221 - 230).
  • WO 97/14686 discloses, amongst other compounds, aminospiropiperidine quinazoline derivatives of the following formula:
  • R represents various substituents, for use as pharmaceuticals.
  • the treatment or prophylaxis of inflammatory conditions is disclosed as a particular pharmaceutical use. Disclosure of the invention
  • R and R independently represent hydrogen, Cl to 6 alkyl, C2 to 6 alkenyl, C2 to 6 alkynyl, Cl to 6 alkoxy, Cl to 6 alkylthio, halogen, hydroxy, trifluoromethyl or amino;
  • R represents one or more substituents independently selected from hydrogen, Cl to 6 alkyl, C2 to 6 alkenyl, C2 to 6 alkynyl, Cl to 6 alkoxy, Cl to 6 alkylthio, halogen, hydroxy, trifluoromethyl, amino, cyano, nitro, trifluoromethoxy, methanesulphonyl, sulphamoyl, -NR R , -COOR , -CONR R , benzyloxy, phenyl, or a 5-membered heterocyclic aromatic ring containing 1 to 3 heteroatoms which may be the same or different and are selected from O, N and S, which phenyl or 5-membered heterocyclic aromatic ring is optionally substituted, the optional substituents being Cl to 6 alkyl, halogen, cyano, nitro, hydroxy, Cl to 6 alkoxy, trifluoromethyl and trifluoromethoxy;
  • R , R and R independently represent hydrogen or Cl to 6 alkyl
  • R and R independently represent hydrogen, Cl to 6 alkyl or phenyl, which phenyl is optionally substituted by one or more groups independently selected from Cl to 6 alkyl, halogen, cyano, nitro, hydroxy, C 1 to 6 alkoxy, trifluoromethyl and trifluoromethoxy;
  • X represents O, NR or S(O) n wherein n represents zero, 1 or 2; 9 R represents hydrogen or Cl to 6 alkyl; and
  • A represents an aromatic carbocyclic ring or a pyridyl ring
  • the compounds of formula (I) and their pharmaceutically acceptable salts, enantiomers, racemates and tautomers have the advantage that they are inhibitors of the enzyme nitric oxide synthase (NOS).
  • NOS nitric oxide synthase
  • the compounds of formula (I) and their pharmaceutically acceptable salts, enantiomers, racemates and tautomers have the advantage that they are inhibitors of the inducible isoform of the enzyme nitric oxide synthase (iNOS) present in many cells, particularly macrophages.
  • the invention further provides a process for the preparation of such compounds or a pharmaceutically acceptable salt, enantiomer, racemate or tautomer thereof.
  • Another aspect of the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate or tautomer thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial.
  • a more particular aspect of the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate or tautomer thereof, in the manufacture of a medicament, for the treatment or prophylaxis of inflammatory disease.
  • a method of treating, or reducing the risk of, diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial which comprises administering to a person suffering from or at risk of, said disease or condition, a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate or tautomer thereof.
  • a method of treating, or reducing the risk of, inflammatory disease in a person suffering from or at risk of, said disease comprises administering to the person a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate or tautomer thereof.
  • the compounds of the present invention may also be used advantageously in combination with a second pharmaceutically active substance, particularly in combination with a selective inhibitor of the inducible isoform of cyclooxygenase (COX-2).
  • COX-2 cyclooxygenase
  • a method of treating, or reducing the risk of, inflammation, inflammatory disease and inflammatory related disorders in a person suffering from or at risk of, said disease or condition comprises administering to the person a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate or tautomer thereof in combination with a COX-2 inhibitor.
  • a in formula (I) represents a phenyl ring.
  • a in formula (I) represents a pyridyl ring.
  • R in formula (I) represents fluoro. More preferably, R in formula (I) represents 5 -fluoro. 2
  • R in formula (I) represents hydrogen or fluoro, more preferably hydrogen or
  • R in formula (I) represents halogen or cyano, more preferably chloro or cyano.
  • X represents O.
  • Particular compounds of the invention include:
  • Cl to 6 alkyl denotes a straight or branched chain alkyl group having from 1 to 6 carbon atoms or a cyclic alkyl group having from 3 to 6 carbon atoms. Examples of such groups include methyl, ethyl, n-propyl, i- propyl, n-butyl, i-butyl, t-butyl, cyclopentyl and cyclohexyl.
  • C2 to 6 alkenyl denotes a straight or branched chain alkyl group having from 2 to 6 carbon atoms and including one double bond or a cyclic alkyl group having from 3 to 6 carbon atoms and including one double bond.
  • Examples of such groups include ethenyl, 1- and 2-propenyl, 2-methyl-2-propenyl, 2-butenyl, cyclopentenyl and cyclohexenyl.
  • C2 to 6 alkynyl referred to herein denotes a straight or branched chain alkyl group having from 2 to 6 carbon atoms and including one triple bond. Examples of such groups include ethynyl, 1- and 2-propynyl and 2-butynyl.
  • Cl to 6 alkoxy denotes a straight or branched chain alkoxy group having from 1 to 6 carbon atoms. Examples of such groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, s-butoxy and t-butoxy.
  • Examples of said "5-membered heterocyclic aromatic ring containing 1 to 3 heteroatoms" include furan, thiophene, pyrrole, thiazole, oxazole, imidazole, pyrazole, isoxazole, isothiazole, oxadiazole, thiadiazole, triazole and the like.
  • R 1 and R 2 are as defined above, with a compound of formula (III), or a protected derivative thereof,
  • R , A and X are as defined above.
  • the reaction may be carried out in a polar solvent, for example, methanol, ethanol, acetonitrile, dimethylformamide or dimethylsulphoxide at a suitable temperature, generally between 20 °C and the boiling point of the solvent, or without solvent at a temperature generally between 20 °C and 200 °C.
  • a polar solvent for example, methanol, ethanol, acetonitrile, dimethylformamide or dimethylsulphoxide
  • a suitable temperature generally between 20 °C and the boiling point of the solvent, or without solvent at a temperature generally between 20 °C and 200 °C.
  • acetal such as the diethoxy acetal.
  • the process is then preferably carried out in the presence of an acid catalyst.
  • the required acetals may be formed by reacting an unprotected compound of formula (HI) with an alcohol such as ethanol using methods that are well known in the art.
  • the present invention includes compounds of formula (I) in the form of salts, in particular acid addition salts.
  • Suitable salts include those formed with both organic and inorganic acids.
  • Such acid addition salts will normally be pharmaceutically acceptable although salts of non-pharmaceutically acceptable acids may be of utility in the preparation and purification of the compound in question.
  • preferred salts include those formed from hydrochloric, hydrobromic, sulphuric, phosphoric, citric, tartaric, lactic, pyruvic, acetic, succinic, fumaric, maleic, methanesulphonic and benzenesulphonic acids.
  • Salts of compounds of formula (I) may be formed by reacting the free base, or a salt, enantiomer, racemate or tautomer thereof, with one or more equivalents of the appropriate acid.
  • the reaction may be carried out in a solvent or medium in which the salt is insoluble or in a solvent in which the salt is soluble, for example, water, dioxane, ethanol, tetrahydrofuran or diethyl ether, or a mixture of solvents, which may be removed in vacuo or by freeze drying.
  • the reaction may also be a metathetical process or it may be carried out on an ion exchange resin.
  • Novel intermediates of formulae (H) and (HI) form another aspect of the invention.
  • R , A and X are as defined above and P represents hydrogen or a protecting group.
  • suitable protecting groups include acetyl and trimethylsilyl.
  • P represents hydrogen
  • the cyclisation reaction may occur spontaneously or upon treatment of the compound of formula (IV) with a base such as triethylamine or sodium hydroxide.
  • P represents a protecting group
  • the acidic or basic conditions used to remove the protecting group generally also serve to effect the cyclisation reaction.
  • R , A, X and P are as defined above, and L is a leaving group.
  • the reaction may be performed in an organic solvent, for example ethanol, dichloromethane or dimethylformamide at a temperature between 0 C and the boiling point of the solvent.
  • the reaction may be catalysed by the addition of a base; bases that may be used include organic amines (for example, triethylamine or pyridine) and alkali metal hydroxides, alkoxides or hydrides.
  • Suitable leaving groups, L include halogen (especially chlorine) and hydroxy 1.
  • reaction between compounds of formulae (V) and (VI) may also be achieved using a suitable coupling agent such as CDI (1,1'- carbonyldiimidazole) , DCC (1,3-dicyclohexylcarbodiimide) or HOBt (1- hydroxybenzotriazole).
  • a suitable coupling agent such as CDI (1,1'- carbonyldiimidazole) , DCC (1,3-dicyclohexylcarbodiimide) or HOBt (1- hydroxybenzotriazole).
  • the compounds of formula (IV) may not be isolated as such from the above reactions, since spontaneous cyclisation will have occurred to give compounds of formula (HI).
  • the compounds of the invention and intermediates thereto may be isolated from their reaction mixtures and, if necessary further purified, by using standard techniques.
  • the compounds of formula I may exist in enantiomeric forms. Therefore, all enantiomers, diastereomers, racemates and mixtures thereof are included within the scope of the invention.
  • the various optical isomers may be isolated by separation of a racemic mixture of the compounds using conventional techniques, for example, fractional crystallisation, or HPLC.
  • Intermediate compounds may also exist in enantiomeric forms and may be used as purified enantiomers, diastereomers, racemates or mixtures.
  • the compounds of formula (I) may exist in alternative tautomeric forms.
  • Compounds of formula (I) are provided in another tautomeric form or as a mixture thereof.
  • the compounds of formula (I), and their pharmaceutically acceptable salts, enantiomers, racemates and tautomers, are useful because they possess pharmacological activity in animals.
  • the compounds are active as inhibitors of the enzyme nitric oxide synthase. More particularly, they are inhibitors of the inducible isoform of the enzyme nitric oxide synthase present in macrophages and as such are predicted to be useful in therapy, for example, as anti-inflammatory agents.
  • the compounds may also have utility as inhibitors of nNOS.
  • the compounds and their pharmaceutically acceptable salts, enantiomers, racemates and tautomers are indicated for use in the treatment or prophylaxis of diseases or conditions in which synthesis or oversynthesis of nitric oxide synthase forms a contributory part.
  • the compounds are indicated for use in the treatment of inflammatory conditions in mammals including man.
  • osteoarthritis rheumatoid arthritis, rheumatoid spondylitis, gouty arthritis and other arthritic conditions, inflamed joints;
  • inflammatory eye conditions including uveitis and conjunctivitis;
  • lung disorders in which inflammation is involved for example, asthma, bronchitis, pigeon fancier's disease, farmer's lung, acute respiratory distress syndrome;
  • bacteraemia bacteraemia, endotoxaemia (septic shock), aphthous ulcers, gingivitis, pyresis, pain and pancreatitis;
  • gastrointestinal tract conditions of the gastrointestinal tract including Crohn's disease, inflammatory bowel disease, atrophic gastritis, gastritis varialoforme, ulcerative colitis, coeliac disease, regional ileitis, peptic ulceration, irritable bowel syndrome, damage to the gastrointestinal tract resulting from infections by, for example, Helicobacter pylori, or from treatments with non-steroidal anti- inflammatory drugs;
  • the compounds will also be useful in the treatment and alleviation of acute pain or persistent inflammatory pain or neuropathic pain or pain of a central origin.
  • the compounds of formula (I) and their pharmaceutically acceptable salts, enantiomers, racemates and tautomers may also be useful in the treatment or prophylaxis of diseases or conditions in addition to those mentioned above.
  • the compounds may be useful in the treatment of atherosclerosis, cystic fibrosis, hypotension associated with septic and/or toxic shock, in the treatment of dysfunction of the immune system, as an adjuvant to short- term immunosuppression in organ transplant therapy, in the treatment of vascular complications associated with diabetes and in cotherapy with cytokines, for example TNF or interleukins.
  • the compounds of formula (I) may also show inhibitory activity against the neuronal isoform of nitric oxide synthase.
  • they may also be useful in the treatment of hypoxia, for example in cases of cardiac arrest and stroke, neurodegenerative disorders including nerve degeneration and/or nerve necrosis in disorders such as ischaemia, hypoxia, hypoglycaemia, epilepsy, and in external wounds (such as spinal cord and head injury), hyperbaric oxygen convulsions and toxicity, dementia, for example pre-senile dementia, Alzheimer's disease and ATDS-related dementia, Sydenham's chorea, Parkinson's disease, Tourette's Syndrome, Huntington's disease, Amyotrophic Lateral Sclerosis, Korsakoffs disease, imbecility relating to a cerebral vessel disorder, sleeping disorders, schizophrenia, depression, pain, autism, seasonal affective disorder, jet-lag, depression or other symptoms associated with
  • Premenstrual Syndrome Pain and anxiety.
  • Compounds of formula (I) may also be expected to show activity in the prevention and reversal of tolerance to opiates and diazepines, treatment of drug addiction, treatment of migraine and other vascular headaches, neurogenic inflammation, in the treatment of gastrointestinal motility disorders, cancer and in the induction of labour.
  • Prophylaxis is expected to be particularly relevant to the treatment of persons who have suffered a previous episode of, or are otherwise considered to be at increased risk of, the disease or condition in question.
  • Persons at risk of developing a particular disease or condition generally include those having a family history of the disease or condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the disease or condition.
  • the dosage administered will, of course, vary with the compound employed, the mode of administration and the treatment desired. However, in general, satisfactory results are obtained when the compounds are administered at a dosage of the solid form of between 1 mg and 2000 mg per day.
  • the compounds of formula (I), and pharmaceutically acceptable derivatives thereof may be used on their own, or in the form of appropriate pharmaceutical compositions in which the compound or derivative is in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.
  • Administration may be by, but is not limited to, enteral (including oral, sublingual or rectal), intranasal, intravenous, topical or other parenteral routes.
  • enteral including oral, sublingual or rectal
  • intranasal intranasal
  • intravenous topical or other parenteral routes.
  • Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, "Pharmaceuticals - The Science of Dosage Form Designs", M. E. Aulton, Churchill Livingstone, 1988.
  • the pharmaceutical composition preferably comprises less than 80% and more preferably less than 50% of a compound of formula (I), or a pharmaceutically acceptable salt, enantiomer, racemate or tautomer thereof.
  • the compounds of formula (I), and pharmaceutically acceptable derivatives thereof, may also be advantageously used in combination with a COX-2 inhibitor.
  • COX-2 inhibitors are Celecoxib and MK-966.
  • the NOS inhibitor and the COX-2 inhibitor may either be formulated together within the same pharmaceutical composition for administration in a single dosage unit, or each component may be individually formulated such that separate dosages may be administered either simultaneously or sequentially.
  • the title compound was prepared following the method of Preparation 1 but using 2- thioacetoxybenzoic acid chloride.
  • the product was obtained as a yellow gum which was a mixture of rotamers by 300 MHz H NMR spectroscopy.
  • Examples 5 and 6 were obtained from 2-amino-6-fluorobenzamidine dihydrochloride and 2-chloro-5a,6,8,9-tetrahydropyrido[2,l-b][l,3]benzoxazine-7,l 1-dione (Preparation 5).
  • the activity of compounds of formula (I), or a pharmaceutically acceptable salt, enantiomer or tautomer thereof, may be screened for nitric oxide synthetase inhibiting activity by a procedure based on that of F ⁇ rstermann et al, Eur. J. Pharm., 1992, 225, 161-165.
  • Nitric oxide synthase converts 3 H-L-arginine into 3 H-L-citrulline which can be separated by cation exchange chromatography and quantified by liquid scintillation counting.
  • Enzyme is prepared, after induction, from the cultured murine macrophage cell line J774A-1 (obtained from the laboratories of the Imperial Cancer Research Fund). J774A-1 cells are cultured in Dulbeccos Modified Eagles Medium (DMEM) supplemented with 10% foetal bovine serum, 4 mM L-glutamine and antibiotics (100 units/ml penicillin G, 100 mg/ml streptomycin & 0.25 mg/ml amphotericin B). Cells are routinely grown in 225 cm 3 flasks containing 35 ml medium kept at 37 °C and in a humidified atmosphere containing 5% CO 2 .
  • DMEM Dulbeccos Modified Eagles Medium
  • Nitric oxide synthase is produced by cells in response to interferon-g (EFNg) and lipopolysaccharide (LPS).
  • the medium from confluent culture flasks is removed and replaced with 25 ml (per flask) of fresh medium containing 1 mg/ml LPS and 10 units/ml IFNg.
  • harvesting of cells is accomplished by scraping the cell sheet from the flask surface into the culture medium.
  • Cells are collected by centrifugation (1000 g for 10 minutes) and lysate prepared by adding to the cell pellet a solution containing 50 mM Tris-HCl (pH 7.5 at 20 °C), 10% (v/v) glycerol, 0.1% (v/v) Triton-X-100, 0.1 mM dithiothreitol and a cocktail of protease inhibitors comprising leupeptin (2 mg/ml), soya bean trypsin inhibitor (10 mg/ml), aprotinin (5 mg/ml) and phenylmethylsulphonyl fluoride (50 mg/ml).
  • protease inhibitors comprising leupeptin (2 mg/ml), soya bean trypsin inhibitor (10 mg/ml), aprotinin (5 mg/ml) and phenylmethylsulphonyl fluoride (50 mg/ml).
  • substrate cocktail 50 mM Tris-HCl (pH 7.5 at 20 °C), 400 ⁇ M NADPH, 20 ⁇ M flavin adenine dinucleotide, 20 ⁇ M flavin mononucleotide, 4 ⁇ M tetrahydrobiopterin, 12 ⁇ M L-arginine and 0.025 mCi L-[ 3 H] arginine
  • substrate cocktail 50 mM Tris-HCl (pH 7.5 at 20 °C), 400 ⁇ M NADPH, 20 ⁇ M flavin adenine dinucleotide, 20 ⁇ M flavin mononucleotide, 4 ⁇ M tetrahydrobiopterin, 12 ⁇ M L-arginine and 0.025 mCi L-[ 3 H] arginine
  • the reaction is started by adding 50 ⁇ l of cell lysate (prepared as above) and after incubation for 1 hour at room temperature is terminated by addition of 50 ⁇ l of an aqueous solution of 3 mM nitroarginine and 21 mM EDTA.
  • Labelled L-citrulline is separated from labelled L-arginine using Dowex AG-50W.
  • 150 ⁇ l of a 25% aqueous slurry of Dowex 50W (Na + form) is added to the assay after which the whole is filtered into 96 well plates.
  • 75 ⁇ l of filtrate is sampled and added to wells of 96 well plates containing solid scintillant. After allowing the samples to dry the L-citrulline is quantified by scintillation counting.
  • basal activity is 300 dpm per 75 ⁇ l sample which is increased to 1900 dpm in the reagent controls.
  • Compound activity is expressed as IC 0 (the concentration of drug substance which gives 50% enzyme inhibition in the assay) and aminoguanidine, which gives an IC 50 (50% inhibitory concentration) of 10 ⁇ M, is tested as a standard to verify the procedure.
  • Compounds are tested at a range of concentrations and from the inhibitions obtained IC 0 values are calculated.
  • Compounds that inhibit the enzyme by at least 25% at 100 ⁇ M are classed as being active and are subjected to at least one retest. In the above screen, the compounds of Examples 1 to 6 were tested and gave IC50 values of less than 25 ⁇ M indicating that they are expected to show useful therapeutic activity.
  • Compounds also show activity against the human form of induced nitric oxide synthase as can be demonstrated in the following assay.
  • Enzyme is prepared, after induction, from the cultured human colon adrenocarcinoma cell line DLDl (obtained from the European Collection of Animal Cell Culture - cell line number 90102540).
  • DLDl cells are cultured in RPMI 1640 medium supplemented with 10% foetal bovine serum, 4 mM L-glutamine and antibiotics (100 units/ml penicillin G, 100 ⁇ g/ml streptomycin and 0.25 ⁇ g/ml amphotericin B). Cells are routinely grown in 225 cm flasks containing 35 ml medium kept at 37 °C and in a humidified atmosphere containing 5% CO 2 .
  • Nitric oxide synthase is produced by cells in response to interferon- ⁇ (IFN- ⁇ ) and interleukin- 1 ⁇ (IL-l ⁇ ).
  • IFN- ⁇ interferon- ⁇
  • IL-l ⁇ interleukin- 1 ⁇
  • the medium from confluent flasks is removed and replaced with 25 ml (per flask) of fresh medium containing 250 units/ml IL-l ⁇ and 1000 units/ml IFN- ⁇ .
  • harvesting of cells is accomplished by scraping the cell monolayer from the flask surface into the culture medium.
  • Cells are collected by centrifugation (lOOOg for 10 minutes) and lysate prepared by adding to the cell pellet a solution containing 50 mM Tris-HCl (pH 7.5 at 20°C), 10% (v/v) glycerol, 0.1% (v/v) Triton-XlOO, 0.1 mM dithiothreitol and a cocktail of protease inhibitors including leupeptin (2 ⁇ g/ml), soya bean trypsin inhibitor (10 ⁇ g/ml), aprotonin (5 ⁇ g/ml) and phenylmethylsulphonyl fluoride (50 ⁇ g/ml).
  • substrate cocktail 50 mM Tris-HCl (pH 7.5), 400 ⁇ M NADPH, 20 ⁇ M flavin adenine dinucleotide, 20 ⁇ M flavin mononucleotide and 4 ⁇ M tetrahydrobiopterin
  • substrate cocktail 50 mM Tris-HCl (pH 7.5), 400 ⁇ M NADPH, 20 ⁇ M flavin adenine dinucleotide, 20 ⁇ M flavin mononucleotide and 4 ⁇ M tetrahydrobiopterin
  • Test compounds are preincubated with enzyme by adding together with 40 ⁇ l of cell lysate (prepared as above) and incubating for 1 hour at 37 °C at the end of which period 10 ⁇ l of 30 ⁇ M L-arginine and 0.025 ⁇ Ci of L-[ 3 H]-arginine in 50 mM Tris-HCl is added to start the enzymatic reaction. Incubation is continued for a further 1 hour at 37 °C. The reaction is terminated by addition of 50 ⁇ l of an aqueous solution of 3 mM nitroarginine and 21 mM EDTA.
  • Labelled L-citrulline is separated from labelled L-arginine using Dowex AG-50W. 120 ⁇ l of a 25% aqueous slurry of Dowex 50W is added to 96 well filter plates (0.45 ⁇ m pore size). To this is added 120 ⁇ l of terminated assay mix. 75 ⁇ l of filtrate is sampled and added to the wells of 96 well plates containing solid scintillant. After allowing the samples to dry the L-citrulline is quantified by scintillation counting.
  • basal activity is 300 dpm per 75 ⁇ l sample of reagent controls, which is increased to 3000 dpm in the presence of enzyme.
  • Compound activity is expressed as IC 50 (the concentration of drug substance which gives 50% enzyme inhibition in the assay) and L-NMMA, which gives an IC 50 of about 0.4 ⁇ M is tested as a standard to verify the procedure.
  • IC 50 the concentration of drug substance which gives 50% enzyme inhibition in the assay
  • L-NMMA which gives an IC 50 of about 0.4 ⁇ M is tested as a standard to verify the procedure.
  • Compounds are tested at a range of concentrations and from the inhibitions obtained IC 50 values are calculated.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouveaux composés de la formule (I) où A représente un noyau carbocyclique aromatique ou un noyau pyridyle; X représente O, NR9 ou S(O)¿n?, où n vaut 0,1 ou 2; et R?1, R2 et R3¿ sont comme définis dans la spécification. L'invention concerne également leurs sels pharmaceutiquement acceptables et leurs énantiomères et tautomères ainsi que leurs procédés de production, les compositions les contenant et leur utilisation en thérapie. Ces composés inhibent la synthase d'oxyde nitrique et sont particulièrement utiles dans le traitement ou la prophylaxie de maladies et douleurs inflammatoires.
PCT/SE1999/001318 1998-07-31 1999-07-27 Composes WO2000006576A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU56613/99A AU5661399A (en) 1998-07-31 1999-07-27 Compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9802650A SE9802650D0 (sv) 1998-07-31 1998-07-31 Compounds
SE9802650-3 1998-07-31

Publications (1)

Publication Number Publication Date
WO2000006576A1 true WO2000006576A1 (fr) 2000-02-10

Family

ID=20412181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1999/001318 WO2000006576A1 (fr) 1998-07-31 1999-07-27 Composes

Country Status (3)

Country Link
AU (1) AU5661399A (fr)
SE (1) SE9802650D0 (fr)
WO (1) WO2000006576A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103275105A (zh) * 2012-08-07 2013-09-04 河北大学 一种氮杂糖并噻嗪烷酮衍生物及合成方法和其在药物制剂中的应用
WO2022195579A1 (fr) 2021-03-15 2022-09-22 Saul Yedgar Dipalmitoyl-phosphatidyl-éthanol-amine conjuguée à l'acide hyaluronique en combinaison avec des médicaments anti-inflammatoires non stéroïdiens (ains) pour traiter ou soulager des maladies inflammatoires

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No relevant documents have been disclosed. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103275105A (zh) * 2012-08-07 2013-09-04 河北大学 一种氮杂糖并噻嗪烷酮衍生物及合成方法和其在药物制剂中的应用
CN103275105B (zh) * 2012-08-07 2015-03-04 河北大学 一种氮杂糖并噻嗪烷酮衍生物及合成方法和其在药物制剂中的应用
WO2022195579A1 (fr) 2021-03-15 2022-09-22 Saul Yedgar Dipalmitoyl-phosphatidyl-éthanol-amine conjuguée à l'acide hyaluronique en combinaison avec des médicaments anti-inflammatoires non stéroïdiens (ains) pour traiter ou soulager des maladies inflammatoires

Also Published As

Publication number Publication date
AU5661399A (en) 2000-02-21
SE9802650D0 (sv) 1998-07-31

Similar Documents

Publication Publication Date Title
US6303613B1 (en) Aminopyrimidine derivatives, processes for their preparation, compositions containing them and their use as pharmaceuticals
WO2000021934A1 (fr) Composes
WO1996006843A1 (fr) Nouveau derive de naphtyridine et composition medicinale a base de ce derive
EP1562920B1 (fr) 3-arylthio-3-thiazolyl-alkylamines anti-inflammatoires
EP3099302B1 (fr) Formes crystallines de 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-méthylcyclohexylamino)-pyrimidine-5-carboxamide
US6083952A (en) Compounds
US6100246A (en) Spiro-piperidine derivatives as inhibitors of nitric oxide synthase
WO2000006576A1 (fr) Composes
US7329686B2 (en) Substituted thiophene compounds
EP1539731B9 (fr) Nouveaux composes
WO2023212237A1 (fr) Compositions utiles pour moduler l'épissage
MXPA99009188A (en) Compounds
CA3204133A1 (fr) Derives d'indole en tant qu'inhibiteurs de kinase
WO2000064904A1 (fr) Derives d'amidine 5,7-bicyclique utiles en tant qu'inhibiteurs de l'oxyde nitrique synthase
MXPA99011983A (en) Compounds
CZ9904752A3 (cs) Deriváty aminospivopiperidinchinazolinu
CZ367499A3 (cs) Sloučeniny
EP1611100A1 (fr) Nouveaux derives de 2-aminopyridine substituee en n

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 09380380

Country of ref document: US

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase